This review is an update of an earlier narrative review published in 2015 on developments
in the clinical management of cutaneous leishmaniasis (CL) including diagnosis, treatment …

This review focuses on recent developments in the diagnosis, treatment, management, and
strategies for the prevention and control of cutaneous leishmaniasis (CL) caused by both …

The leishmaniases are diseases caused by pathogenic protozoan parasites of the genus
Leishmania. Infections are initiated when a sand fly vector inoculates Leishmania parasites …

Leishmaniasis is a neglected tropical disease that affects 12 million people worldwide. The
disease has high morbidity and mortality rates and is prevalent in over 80 countries, leaving …

Leishmaniases remain a major public health problem today despite the vast amount of
research conducted on Leishmania pathogens. The biological model is genetically and …

Background Cutaneous leishmaniasis (CL) is treated with parenteral drugs for decades with
decreasing rate cures. Miltefosine is an oral medication with anti-leishmania activity and …

Background Leishmania (Viannia) braziliensis is a parasite recognized as the most
important etiologic agent of mucosal leishmaniasis (ML) in the New World. In Amazonia …

Human infection with Leishmania braziliensis leads to the establishment of cutaneous
leishmaniasis (CL), characterized by the appearance of skin lesions that progress from …

Studies in the recent years have advanced the knowledge of how host and parasite factors
contribute to the pathogenesis of human tegumentary leishmaniasis. Polymorphism within …

Abstract The Health Post of Corte de Pedra is located in a region endemic for American
tegumentary leishmaniasis (ATL) in the Brazilian state of Bahia, and it treats 500–1,300 …